They reported BRAF inhibitors (Sorafenib, PLX4032, GSK2118436, RAF-265, XL281), inhibitors of c-kit tyrosine kinase activity (Imatinib, Sunitinib, Dasatinib, Nilotinib), and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies (Ipilimumab and Tremelimumab), which showed the best test results in patients with melanoma (57). Here, BRAF is linked to melanoma.